Developing and commercializing first-in-class, well-characterized drugs for life-threatening, rare and ultra-rare diseases with high unmet medical needs and no approved therapies.

Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

PALO ALTO, Calif. , Oct. 1, 2021 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported that, in connection with the

Eiger BioPharmaceuticals Appoints Erik Atkisson as General Counsel and Chief Compliance Officer

PALO ALTO, Calif. , Sept. 21, 2021 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced the appointment of Erik

Eiger BioPharmaceuticals Announces Interim Analysis and Continuation of Dosing of Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Outpatients

- Data Safety Monitoring Board recommends continuation of Peginterferon Lambda - Interim analysis of 453 patients, randomized 1:1 Peginterferon Lambda vs placebo PALO ALTO, Calif., Sept. 20, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical